TRIAMINIC-12
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIAMINIC-12 (TRIAMINIC-12).
Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion. Chlorpheniramine is an antihistamine that competitively antagonizes histamine H1 receptors, preventing histamine-mediated symptoms such as sneezing, rhinorrhea, and pruritus.
| Metabolism | Pseudoephedrine is partially metabolized in the liver by N-demethylation to norpseudoephedrine, with about 70-90% excreted unchanged in urine. Chlorpheniramine is extensively metabolized in the liver via CYP2D6 and other pathways, including N-demethylation and oxidative deamination. |
| Excretion | Triaminic-12 contains chlorpheniramine and pseudoephedrine. Chlorpheniramine: ~50% renal as metabolites, <1% unchanged. Pseudoephedrine: ~70-90% renal unchanged, remainder as metabolites. Total elimination: renal > 90%, fecal < 10%. |
| Half-life | Chlorpheniramine: 12-15 hours (terminal) in adults, extended in hepatic impairment or elderly. Pseudoephedrine: 5-8 hours (terminal) in adults with normal renal function, prolonged in renal impairment (up to 20 hours). The combination product's duration is determined by chlorpheniramine. |
| Protein binding | Chlorpheniramine: ~70% bound to plasma proteins (mainly albumin). Pseudoephedrine: negligible binding (<10%). |
| Volume of Distribution | Chlorpheniramine: 3-4 L/kg (widespread distribution, including CNS). Pseudoephedrine: 2-3 L/kg (distributes into body tissues). |
| Bioavailability | Chlorpheniramine oral: ~25-50% due to first-pass metabolism (extensive hepatic CYP450). Pseudoephedrine oral: ~75-100% well absorbed, minimal first-pass. |
| Onset of Action | Oral: Chlorpheniramine onset 30-60 minutes; Pseudoephedrine onset 30-60 minutes. |
| Duration of Action | Chlorpheniramine: 4-6 hours for antihistamine effect, up to 12-24 hours for suppression of wheal/flare. Pseudoephedrine: 4-6 hours oral. The product's extended-release formulation provides up to 12 hours of symptom relief. |
| Molecular Weight | Chlorpheniramine maleate: 390.86 Da; Pseudoephedrine HCl: 201.69 Da. Combined product: variable. |
Oral: 1 tablet (75 mg of pseudoephedrine hydrochloride and 4 mg of chlorpheniramine maleate) every 12 hours, not to exceed 2 tablets in 24 hours.
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | Contraindicated in severe renal impairment (CrCl <30 mL/min). For moderate impairment (CrCl 30-50 mL/min), reduce frequency to every 24 hours. No adjustment for mild impairment. |
| Liver impairment | Contraindicated in Child-Pugh class C. For Child-Pugh class A or B, use with caution and consider reducing dose frequency to every 24 hours due to increased half-life. |
| Pediatric use | Not recommended for children under 12 years. For children 12 years and older, use adult dosing. |
| Geriatric use | For patients >65 years: use with caution due to increased risk of anticholinergic effects and potential for hypertension or tachycardia. Consider starting with 1 tablet every 24 hours and monitor response. |
| 1st trimester | Triaminic-12 contains chlorpheniramine and pseudoephedrine. Chlorpheniramine is generally avoided in first trimester due to potential teratogenic effects (limited data). Pseudoephedrine may be associated with gastroschisis in first trimester. |
| 2nd trimester | Second trimester use may be acceptable if benefit outweighs risk; pseudoephedrine may reduce uterine blood flow. |
| 3rd trimester | Third trimester: avoid pseudoephedrine near term due to risk of uterine vasoconstriction and neonatal irritability. Chlorpheniramine is generally safer but may cause neonatal withdrawal if used chronically. |
Clinical note
Comprehensive clinical and safety monograph for TRIAMINIC-12 (TRIAMINIC-12).
| Placental transfer | Both chlorpheniramine and pseudoephedrine cross the placenta. Pseudoephedrine has documented transfer with fetal exposure. |
| Breastfeeding | Chlorpheniramine passes into breast milk in small amounts; may cause drowsiness or irritability in infant. Pseudoephedrine is excreted in breast milk and may cause irritability or decreased milk production. Use lowest effective dose for shortest duration. |
■ FDA Black Box Warning
None
| Serious Effects |
Severe hypertensionCoronary artery diseaseMAOI therapy currently or within 14 daysNarrow-angle glaucomaUrinary retention (e.g., due to prostatic hypertrophy)Severe renal impairment (CrCl < 30 mL/min)
| Precautions | Use with caution in patients with hypertension, cardiovascular disease, diabetes, hyperthyroidism, increased intraocular pressure, prostatic hypertrophy, or urinary retention. May cause dizziness or drowsiness; avoid alcohol and other CNS depressants. Do not exceed recommended dosage. Not for use in children under 12 years. |
| Food/Dietary | Avoid high-tyramine foods (e.g., aged cheeses, cured meats) if taking MAOIs (contraindicated). Caffeine may increase stimulant effects. Alcohol increases sedation. Grapefruit juice may affect metabolism of pseudoephedrine. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Triaminic-12 (acetaminophen 500 mg, pseudoephedrine 30 mg, dextromethorphan 15 mg, chlorpheniramine 4 mg): Acetaminophen is generally considered low risk in all trimesters; pseudoephedrine is associated with a possible increased risk of gastroschisis in the first trimester; dextromethorphan has limited data but no clear teratogenic signal; chlorpheniramine is considered safe in pregnancy. FDA pregnancy category varies by component: acetaminophen B, pseudoephedrine C, dextromethorphan C, chlorpheniramine B. Overall, avoid in first trimester if possible due to pseudoephedrine. |
| Fetal Monitoring | Monitor maternal blood pressure due to pseudoephedrine; assess fetal heart rate if prolonged use. No specific fetal monitoring required for short-term use. Observe neonate for withdrawal if used near term (pseudoephedrine and chlorpheniramine). |
| Fertility Effects | Acetaminophen may slightly reduce male fertility with prolonged use. Pseudoephedrine and dextromethorphan have no known significant impact on fertility. Chlorpheniramine may cause anticholinergic effects, but no direct fertility impairment. |
| Clinical Pearls | Triaminic-12 contains chlorpheniramine (first-generation antihistamine) and pseudoephedrine (decongestant). Avoid use in patients with hypertension, coronary artery disease, or glaucoma. The antihistamine component causes sedation; caution with driving or operating machinery. Onset of action is 30-60 minutes; duration up to 12 hours. |
| Patient Advice | Take with food to reduce stomach upset. · Do not crush or chew extended-release tablets. · Avoid alcohol and other CNS depressants. · May cause drowsiness; avoid driving until you know how you react. · Do not exceed recommended dose; may cause serious side effects. · Stop and consult doctor if symptoms persist after 7 days or if fever develops. · Do not use if you have high blood pressure, heart disease, or thyroid problems without medical advice. |